Cocrystal Pharma grants stock options to directors, officers, and consultant under 2025 Plan

Cocrystal Pharma, Inc.

Non-qualified stock options granted to 7 directors, 2 executive officers, and 1 consultant, vesting over 1-2 years.
Vesting: 50% on Jan 9, 2027; remaining 50% in 8 quarterly installments starting Mar 31, 2027.
Dr. Roger Kornberg receives 24,615 options (plus $50,000 cash award for SAB chair); James Martin and Sam Lee each receive 49,229.
Directors (excluding executives) each receive 16,410 options; consultant receives 40,000 options.
Options have 10-year term, exercise price set at Jan 8, 2026 closing price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.